Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4526 - The CAN BEAR study: a systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC)

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Supportive Care and Symptom Management;  Targeted Therapy;  Breast Cancer

Presenters

Samuel Martel

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

S. Martel1, M. Bruzzone2, M. Ceppi2, C. Maurer1, N. Falbel Ponde1, A.R. Ferreira1, G. Viglietti3, L. Delmastro4, C. Prady5, E. De Azambuja1, M. Lambertini3

Author affiliations

  • 1 Oncologie Médicale, Institut Jules Bordet, 1000 - Bruxelles/BE
  • 2 Clinical Epidemiology, IRCCS AOU San Martino-IST, National Institute for Cancer Research, 16132 - Genova/IT
  • 3 Breast Cancer Translational Research Laboratory, Institute Jules Bordet, 1000 - Brussels/BE
  • 4 Department Of Oncology, IRCCS AOU, 16132 - San Martino-IST/IT
  • 5 Oncologie Médicale, Hôpital Charles-Lemoyne, J4V 2H1 - Greenfield Park/CA
More

Resources

Abstract 4526

Background

Combining targeted agents and ET improves outcomes in pts with HR+ MBC but increases the risk of AEs. However, the specific additional toxicity burden caused by these agents remains unknown. Our meta-analysis aims to better estimate the comparative risk of AEs with the combination of ET and CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors and anti-HER2 agents in pts with HR+ MBC.

Methods

A systematic literature search of MEDLINE, EMBASE, Cochrane Library and proceedings from major conferences up to March 31st 2017 was conducted to identify randomized controlled trials investigating ET plus CDK4/6, PI3K, mTOR inhibitors and anti-HER2 agents as compared to ET alone in pts with HR+ MBC. For each class of targeted agents, two groups were considered: ET plus targeted agent vs. ET alone. Summary risk estimates (odds ratio, OR) and 95% confidence intervals (CI) were calculated for each side effect within each class of targeted agents for each trial. Pooled analysis was conducted using the random and fixed effects models.

Results

A total of 7865 pts from 15 studies were included in our meta-analysis. Overall, the addition of targeted agents to ET was associated with significant higher risk of grade 3-4 AEs: OR 2.95 (95% CI 2.47-3.53) for CDK4/6 inhibitors, 2.05 (95% CI 1.63-2.58) for PI3K inhibitors, 1.89 (95% CI 1.40-2.56) for mTOR inhibitors, and 2.33 (95% CI 1.17-4.63) for anti-HER2 agents. Anti-HER2 agents, CDK4/6 and PI3K inhibitors significantly increased the risk of grade 3-4 fatigue, but not mTOR inhibitors (OR 1.48; 95% CI 0.64-3.43). Anti-HER2 agents, PI3K and mTOR inhibitors significantly increased the risk of grade 3-4 diarrhea, but not CDK4/6 inhibitors (OR 1.15; 95% CI 0.46-2.87). Other AEs and class specific toxicities will be reported at the conference.

Conclusions

In pts with HR+ MBC, the combination of targeted agents and ET is associated with significant increased risk of AEs. The risk of developing different AEs varies largely according to the type of agent used. Potential specific toxicities should be taken into account and discussed with patients when deciding to opt for combination regimens.

Clinical trial identification

PROSPERO registration number: CRD42017058278

Legal entity responsible for the study

Samuel Martel

Funding

None

Disclosure

E. De Azambuja: Honoraria from Roche and travel grants from Roche and GlaxoSmithKline outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.